SynAct Pharma (OM:SYNACT) - Stock Price, News & Analysis

SYNACT Stock Overview

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden.

About the company

SYNACT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Makes less than USD$1m in revenue (SEK0)

Highly volatile share price over the past 3 months

Earnings have declined by 47.4% per year over past 5 years

Shareholders have been diluted in the past year

+ 1 more risk

SynAct Pharma AB Competitors

Guard Therapeutics International

OM:GUARD

kr299.8m

Active Biotech

OM:ACTI

kr192.8m

Medivir

OM:MVIR

kr309.2m

Curasight

NGM:CURAS

kr.198.1m

Price History & Performance

Summary of all time highs, changes and price drops for SynAct Pharma
Historical stock prices
Current Share Price	kr6.94
52 Week High	kr124.60
52 Week Low	kr4.98
Beta	0.43
1 Month Change	2.36%
3 Month Change	-23.74%
1 Year Change	-90.86%
3 Year Change	-90.03%
5 Year Change	-21.14%
Change since IPO	33.46%

Recent updates

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Sep 04

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Jan 18

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

Shareholder Returns

	SYNACT	SE Biotechs	SE Market
7D	3.5%	2.5%	-0.7%
1Y	-90.9%	-3.4%	4.4%

Return vs Industry: SYNACT underperformed the Swedish Biotechs industry which returned -5.3% over the past year.

Return vs Market: SYNACT underperformed the Swedish Market which returned 10.3% over the past year.

Price Volatility

Is SYNACT's price volatile compared to industry and market?
SYNACT volatility
SYNACT Average Weekly Movement	18.8%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.1%
10% most volatile stocks in SE Market	13.1%
10% least volatile stocks in SE Market	3.5%

Stable Share Price: SYNACT's share price has been volatile over the past 3 months.

Volatility Over Time: SYNACT's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2012	5	Jeppe Ovlesen	synactpharma.com

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.

SynAct Pharma AB Fundamentals Summary

How do SynAct Pharma's earnings and revenue compare to its market cap?
SYNACT fundamental statistics
Market cap	kr246.86m
Earnings (TTM)	-kr215.81m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.1x

P/E Ratio

Is SYNACT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYNACT income statement (TTM)
Revenue	kr0
Cost of Revenue	kr0
Gross Profit	kr0
Other Expenses	kr215.81m
Earnings	-kr215.81m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 31, 2024

Earnings per share (EPS)	-6.07
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SYNACT perform over the long term?

See historical performance and comparison

SYNACT Stock Overview

Rewards

Risk Analysis

SynAct Pharma AB Competitors

OM:GUARD

kr299.8m

OM:ACTI

kr192.8m

OM:MVIR

kr309.2m

NGM:CURAS

kr.198.1m

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

Recent updates

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB Announces Grant of Key European Patent Covering Ap1189

Chief Medical Officer Thierry Duvauchelle has left the company

Synact Pharma AB Announces Positive Data from A Phase 2A Trial of Ap1189 in Covid-19 Infected Patients

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

SynAct Pharma Updates Phase II study with AP1189

Synact Pharma Expands Ap1189 Begin Study in Rheumatoid Arthritis Uk Version

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans